| Summary: | Neisseria gonorrhoeae is the pathogen of gonorrhea. With the widespread use of antibiotics, drug resistance of Neisseria gonorrhoeae is a growing problem. In recent years, drug-resistant strains to the first-line treatment drugs (such as ceftriaxone sodium) have emerged at home and abroad. The WHO has included Neisseria gonorrhoeae as one of the priority pathogens in urgent need of new antibiotics. In recent years, a number of studies have been conducted to evaluate the efficacy of novel antibiotics in the treatment of Neisseria gonorrhoeae, including topoisomerase inhibitors, novel macrolides, pleural polypeptides and small molecule antibacterial drugs, etc. In this article, research progress on the structure, in vitro drug sensitivity, drug resistance mutation, clinical trials and adverse reactions of these drugs was reviewed, aiming to provide references for further research on Neisseria gonorrhoeae and their clinical application.
|
|---|